. 2015 Jul 21;29(11):4461–4472. doi: 10.1096/fj.15-272567

TABLE 6.

Associations between differences in plasma 1-deoxydihydrosphingolipid levels from baseline and changes in neuropathy over time

Deoxydihydrosphingolipid species/type of neuropathy	Sensory	Motor	Autonomic	Total
Total 1-deoxydihydroceramide	0.264	0.095	0.967	0.133
1-Deoxysphinganine	0.205	0.170	0.479	0.721
C₁₄ 1-deoxydihydroceramide	0.050	0.352	0.858	0.237
C₁₆ 1-deoxydihydroceramide	0.280	0.086	0.958	0.132
C₁₈ 1-deoxydihydroceramide	0.196	0.074	0.656	0.077
C18:1 1-deoxydihydroceramide	0.659	0.659	0.014*	0.785
C20 1-deoxydihydroceramide	0.543	0.405	0.896	0.814
C20:1 1-deoxydihydroceramide	0.903	0.073	0.164	0.219
C22 1-deoxydihydroceramide	0.427	0.155	0.773	0.869
C22:1 1-deoxydihydroceramide	0.796	0.016*	0.168	0.233
C24 1-deoxydihydroceramide	0.508	0.101	0.392	0.791
C24:1 1-deoxydihydroceramide	0.607	0.054	0.368	0.546
C26 1-deoxydihydroceramide	0.215	0.409	0.439	0.162
C26:1 1-deoxydihydroceramide	0.191	0.585	0.526	0.228

Main effects of plasma 1-deoxydihydrosphingolipid levels are shown after subtraction from baseline levels. Total neuropathy models were adjusted for hyperlipidemia and body mass index. P values are from mixed models. *P < 0.05.